|
|
|||||||||||||||||
|
|
|
|||||||||||||||||
Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram
Authors: Beadle, B., Canahuate, G., El-Naggar, A., Frank, S., Fuller, D., Garden, A., Gross, N., Gunn, G.B., Hutcheson, K., Lai, S., Lewin, J., Kies, M., Marai, G.E., Mohamed, A., Morrison, W., Mulcahy, C., Phan, J., Rosenthal, D., Sevak, P,, Sheu, T., Vock, D., Weber, R., Zafereo, M.
Publication: Nature Scientific Reports 7, Article 43928 URL: https://www.nature.com/articles/srep43928 Conditional survival (CS), the survival beyond a pre-defined time interval, can identify periods of higher mortality risk for patients with locally advanced laryngeal cancer who face treatment-related toxicity and comorbidities related to alcohol and smoking in the survivorship setting. Using Weibull regression modeling, we analyzed retrospectively abstracted data from 638 records of patients who received radiation to identify prognostic factors for overall survival (OS) and recurrence free survival (RFS) for the first 3 years of survival and for OS conditional upon 3 years of survival. The CS was iteratively calculated, stratifying on variables that were statistically significant on multivariate regression. Predictive nomograms were generated. The median total follow up time was 175 months. The 3- and 6- year actuarial overall survival (OS) was 68% (95% confidence interval [CI] 65-72%) and 49% (CI 45-53%). The 3-year conditional overall survival (COS) at 3 years was 72% (CI 65-74%). Black patients had worse COS over time. Nodal disease was significantly associated with recurrence, but after 3 years, the 3-year conditional RFS converged for all nodal groups. In conclusion, the CS analysis in this patient cohort identified subgroups and time intervals that may represent opportunities for intervention. Support: National Institutes of Health: NCI-R01-CA214825, “SMART-ACT: Spatial Methodologic Approaches for Risk Assessment and Therapeutic Adaptation in Cancer Treatment” Date: March 9, 2017 Document: View PDF |
